Provista on the News

BT Test™

• The BT Test is designed to detect the presence of breast cancer at the molecular level unlike mammography, which only detects masses or gross changes in breast tissue via x-ray imaging.
• The BT Test is an IP protected blood test that offers women a more comfortable test method and greater convenience while providing caregivers higher sensitivity, early detection capabilities, broader range of age applicability and ease of administration.
• The test measures five key cancer-associated biomarkers and when combined and adjusted for age, has shown the potential to detect early stage breast cancer.

RCP-Dx Test™

• The RCP Test is a new diagnostic that screens for these four cancers from a single blood sample. The patented RCP Test is designed to identify distinctive protein patterns in the blood that reflect the presence of four estrogen-related cancers.
• The RCP Test is both highly sensitive and highly specific to this protein, called Riboflavin Carrier Protein (RCP). An accurate screening test for women’s cancers is an essential tool, especially for women in their twenties and thirties for whom mammography has little diagnostic value.
• The RCP Test has demonstrated the ability to detect early and staged breast cancer at better than 92%, more accurate than any other diagnostic on the market today.

LymPro Test®:

• The LymPro Test® is a diagnostic blood test that is 95% accurate and can assist in the early detection and therapeutic intervention of AD when currently approved drugs are most effective.
• Developed and clinically evaluated by the University of Leipzig, a major European medical research university, the Lymphocyte Proliferation Test (LymPro Test) uses two biomarkers to quantify AD. In an initial study evaluation, the LymPro Test demonstrated both a high correlation with clinical AD diagnosis and the potential to diagnose the disease before the appearance of its clinical symptoms.